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A B S T R A C T
The complex genetic diversity of chronic lymphocytic leukemia (CLL) makes it diﬃcult to determine the ef-
fective and durable therapy beneﬁcial to patients. During the several past years' signiﬁcant insights in the
biology of the disease and its treatment have been made, allowing for the identiﬁcation of promising novel
therapeutic agents. The investigation of signaling pathways to understand the biological character of CLL to-
gether with the development of molecular proﬁling is key in personalized approach in therapy for this disease.
As it was already proven, maltotriose (M3) modiﬁed fourth generation poly(propylene imine) dendrimers (PPI-
G4) modulate BCR, TRAIL and WNT signaling pathway gene expression in CLL cells and strongly inﬂuence their
survival by inducing apoptosis and inhibiting proliferation. The aim of this study was to evaluate the inﬂuence of
PPI-G4-M3 dendrimers on NFκB pathway gene expression in CLL (MEC-1) cells with 60 K microarray, as it is one
of the major factors in the pathogenesis of B-cell neoplasms. The ﬁndings were compared with those obtained
with Fludarabine (FA) and the results indicate that PPI-G4-M3 dendrimers aﬀect the expression of the examined
genes and exert comparable eﬀect on the CLL cells to FA. Dendrimers are one of the most potent groups of
nanometer-sized macromolecules for closing the gap between the present ineﬀective treatment and the future
eﬀective personalized therapy due to their potential versatile biological properties.
1. Introduction
Despite the enhanced molecular understanding and the clinical di-
agnosis improvement, chronic lymphocytic leukemia (CLL) still remains
a disease without a well-deﬁned genetic alteration responsible for its
onset (Doménech et al., 2012). As B-CLL cells are characterized by a low
dividing rate, they are less susceptible to chemo- and radiation therapy
commonly used in cancer treatment, which make CLL diﬃcult to cure.
Standard therapy for CLL includes a combination of chemotherapeutics
such as ﬂudarabine (FA), cyclophosphamide and rituximab (FCR) but it
is not suitable for all the patients because of the drug resistance or the
side eﬀects of strong chemotherapy (Smolej, 2016; Tam et al., 2008).
Although the past several years have brought huge and signiﬁcant
changes in therapeutic paradigms of CLL while novel drugs like ibru-
tinib or idelalisib have been approved (Byrd et al., 2015; Ramanathan
et al., 2016), alternative therapeutics approaches are still necessary if
longer survival rates and an ultimately cure in CLL patients are be
achieved.
One of the proposed alternative therapeutic approaches in CLL
treatment is a substitution of a standard chemotherapy by polymeric
therapeutics, which possesses another molecular biological pathway for
inducing apoptosis of CLL cells. For substituting anticancer drug ﬂu-
darabine, open shell (OS) and dense shell (DS) maltotriose (M3)-mod-
iﬁed fourth-generation poly(propylene imine) (PPI-G4) dendrimers
(PPI-G4-OS-M3 or PPI-G4-DS-M3; Fig. 1) have been found and further
validated as possible alternative drug for ﬂudarabine(Franiak-Pietryga
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et al., 2017a; Franiak-Pietryga et al., 2013; Franiak-Pietryga et al.,
2017b). Dendrimers are currently one of the most popular nano-
particles and they have been well described in many previous pub-
lications, e.g. (de Brabander-Van Den Berg and Meijer, 1993; Jain et al.,
2010; Tomalia and Fréchet, 2002; Ziemba et al., 2012a). In short, they
are well-deﬁned, monodisperse, three-dimensional structures with a
central core and functional terminal groups (Tomalia et al., 1985).
Because of their unique structure and properties, dendrimers have at-
tracted great interest in biomedical applications e.g. as polymeric
agents in cancer diagnosis and therapy (Baker, 2009; Kesharwani et al.,
2014; Menjoge et al., 2010; Svenson and Tomalia, 2012).
In previous works it was proved that PPI-G4-OS/DS-M3 dendrimers
reveal low cyto- (Ziemba et al., 2014), geno- (Ziemba et al., 2012b),
hemo-(Ziemba et al., 2012c) and in vivo21 toxicity (Ziemba et al., 2011).
However, it was also indicated that PPI glycodendrimers induce
apoptosis in cancer cells, including CLL, and inhibit their proliferation
without signiﬁcant inﬂuence on normal lymphocytes viability (Franiak-
Pietryga et al., 2013; Ziemba et al., 2014). Moreover, results in one of
our recent study show that PPI-G4-OS-M3 dendrimer signiﬁcantly in-
ﬂuences pro- and antiapoptotic gene and protein expression in CLL cells
(Franiak-Pietryga et al., 2017b).
In this paper, we focused on the inﬂuence of PPI-G4-OS/DS-M3
dendrimers on nuclear factor-κB (NFκB) signaling pathway genes ex-
pression as it is one of the potential targeting patterns for CLL therapy.
NF-κB transcription factors family consists of p65 (RelA), RelB, c-Rel,
p105/p50 (NF-κB1), and p100/52 (NF-κB2) proteins. These proteins
play a meaningful role in inﬂammation and immunity, as well as in cells
proliferation, diﬀerentiation, and survival (Oeckinghaus and Ghosh,
2009). The major role of NF-κB in the pathogenesis of B-cell neoplasms
is well established and a broad array of, mostly extracellular, stimuli
has been reported to directly activate NF-κB in CLL cells (Liu et al.,
2011). The stimuli include: induction of GSK-3 β (Ougolkov et al.,
2007), activation of the Tumor Necrosis Factor receptor (TNFR) family
members, leukemia/lymphoma-1 (TCL1) oncogene deregulation of the
T cell (Liu et al., 2011), activation of Notch signaling (Rosati et al.,
2009), activation of the cell surface receptor CD40 (Polager and
Ginsberg, 2008) or modulation of epigenetic regulators (Chen et al.,
2009). Recent data pointed out that NF-κB is activated by the binding of
unphosphorylated signal transducer and activator of transcription
(STAT3) to the NF-κB dimers p65/p50 in competition with the inhibitor
of NF-κB proteins (IκB) (Liu et al., 2011; Hazan-Halevy et al., 2010).
The present work is part of a series of publications describing the
eﬀect of PPI glycodendrimers on signaling pathway gene expression in
CLL cells. The results of microarray analysis for BCR, TRAIL and WNT
have already been published (Franiak-Pietryga et al., 2017a; Franiak-
Pietryga et al., 2017c; Franiak-Pietryga et al., 2016) and they indicate
that glycodendrimers signiﬁcantly modulate expression of the ex-
amined genes thereby reducing the CLL cells survival. Findings of these
preliminary results might be of an importance considering the usage of
PPI dendrimers as active compounds in the future.
2. Material and methods
2.1. Fludarabine
Commercially available Fludarabine (FA, Genzyme) was used in the
study. Chosen concentration of 1.6 μM is the IC50 of FA in 24-h culture
and was calculated on the basis of previous studies (Ziółkowska et al.,
2012; Zaborowska et al., 2009). It is close to the concentration of the
drug given to patients during the standard treatment protocol (Korycka
and Robak, 2003).
2.2. Dendrimers
Two sets of 4th generation poly(propylene imine) dendrimers (PPI-
G4) with peripheral amino groups modiﬁed with maltotriose units (M3)
in approximately 90% (labeled as the dense shell (DS); PPI-G4-DS-M3)
and 35% (labeled as the open shell (OS); PPI-G4-OS-M3) were used. The
concentration of 8mg/mL was chosen based on the results of our pre-
vious study (Franiak-Pietryga et al., 2015) since it is the IC50 value for
Fig. 1. Simpliﬁed structure of PPI-G4-DS-M3 and PPI-G4-OS-M3 dendrimers.
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PPI-G4-OS-M3 in 48-h culture. Synthesis of the glycodendrimers (GD)
was carried out as described elsewhere (Appelhans et al., 2010;
Mkandawire et al., 2009). The dendrimer structures are given in Fig. 1
and the general characteristics is presented in Table 1.
2.3. Cell culture and treatment
The MEC-1 homogenous cell line with del(17p)(11q) mutation
(DSMZ no. ACC 497) was used. Cells were treated as described in
previous papers (Franiak-Pietryga et al., 2017b; Franiak-Pietryga et al.,
2017c; Franiak-Pietryga et al., 2016). For the treatment cells were in-
cubated with either FA (1.6 μM) or GD (8mg/mL), up to 4 h. Cultures
without GD or FA were used as reference (Ref).
2.4. Microarray gene expression analysis
Microarray gene expression assay (Agilent SurePrint Technologies,
USA) was performed as it was described previously (Franiak-Pietryga
et al., 2017b). Samples were hybridized to an 8× 60 K whole human
genome microarray and the arrays were scanned on an Agilent DNA
Microarray Scanner. Two replicate hybridizations and dye-swap were
carried out for each experiment. All microarray data were deposited at
the Gene Expression Omnibus (GEO) with the accession number
GSE68094.
Microarray data analysis was performed as it was described pre-
viously (Franiak-Pietryga et al., 2017b).
3. Results
3.1. Microarray gene expression proﬁling
We investigated the inﬂuence of PPI-G4-OS/DS-M3 dendrimers on
NFκB pathway genes expression in MEC-1 cells as on the one of the
major factors in the pathogenesis of B-cell neoplasms. We compared the
ﬁndings with results obtained for FA, a drug commonly used in CLL
treatment (Fig. 2).
The gene descriptions and the details concerning their expression
with the p-value indicating diﬀerential expression between the sample
of interest (FA, PPI-G4-OS-M3, PPI-G4-DS-M3) and the Ref are collected
in Table 2. Comparison of gene expression between GD and FA treated
cells is presented in Table 3.
A comparison between PPI-G4-OS-M3 and PPI-G4-DS-M3 den-
drimers mode of action on the cell culture revealed that both groups of
dendrimers induced the same sets of genes (REL, RELB and NFKBIB)
(Table 3). Analogous comparison between FA and dendrimers showed
diﬀerences in the gene expression in the NF-κB signaling pathway. We
have noted that FA in the 4-h culture caused overexpression of REL,
RELB and NFKBIB (Table 2). The heatmap reﬂects signiﬁcant genes
expression diﬀerences in NF-κB signaling pathway under the inﬂuence
of both FA and GD in comparison with reference (FA/Ref and Den-
drimer/Ref), shown in Fig. 3.
4. Discussion
For decades, treatment of CLL has been established on che-
motherapy. Despite the improvement of survival by the use of che-
moimmunotherapy, most patients carrying CLL burden will relapse
eventually. Currently the treatment of patients with CLL is undergoing
fundamental changes (Burger et al., 2017). One promising approach to
achieve more durable responses might be the development of glyco-
dendrimers coated with sugar layer which presents unique and func-
tional characteristics (Kakkar and Balakrishnan, 2015; Eichhorst et al.,
2016).
Following many novel approaches in CLL examination and the
molecular methodology our study is based on the gene expression
proﬁling (GEP) by microarrays to identify the speciﬁc target in CLL
treatment to apply maltotriose-modiﬁed PPI glycodendrimers. In the
current study we found a direct link between diﬀerent expression
proﬁle and the examined compounds. By using the network analysis a
unique gene expression signature composed of three genes: NFKBIA,
BCL3 and CHUK diﬀerentiated between cultures treated with PPI den-
drimers and FA.
Conserved helix-loop-helix ubiquitous kinase (CHUK) encoded by
the CHUK gene is also known as the inhibitor of nuclear factor kappa-B
kinase subunit alpha (IKK-α or IKK1) and it is a part of the IκB kinase
(IKK) complex that plays an important role in regulating the NF-κB
transcription factor.
NF-κB mediates cross-talk between BCR and TNFR signaling
(Rickert et al., 2011). As discussed earlier, activation of the proximal
BCR signaling complex ultimately results in activation of IKK1/IKK2,
phosphorylation and proteosomal degradation of IκBα and induction of
the canonical NF-κB signaling. NF-κB transcriptional activity leads to
upregulation of a number of chemokine molecules (CCL17, CCL22,
CXCR5); cell cycle regulators (Cyclin D) and the anti-apoptotic proteins
mentioned above. In a positive feedback mechanism, canonical NF-κB
signaling enhances transcription of the non-canonical NF-κB pathway
components (such as p100), as well as c-Rel and BAFF-R which are
critical for BAFF-R signaling. Hence the NF-κB pathway represents an
attractive target in B-cell malignancies. Moreover, CD40L- or BAFF-
mediated NF-κB activation has strong clinical implications in that it
may render malignant B cells less dependent on BCR signaling targeting
agents ultimately leading to resistance to BCR-targeting agents (Rickert
et al., 2011). However, our data shows that FA more upregulate the
expression of CHUK gene rather than both glycodendrimers, the dif-
ferences are not very signiﬁcant as well as it is still very short time of
observation (4 h) and we expect diﬀerent results after extended in-
cubation time.
The gene B-cell CLL/lymphoma 3 (BCL3) belongs to IκB family and
was initially identiﬁed as a candidate for a proto-oncogene located
adjacent to the breakpoint of t(14;19)(q32;q13) in some patients with
CLL (Nishikori et al., 2003; McKeithan et al., 1994; Ohno et al., 1990;
Chang and Vancurova, 2014; Mckeithan et al., 1997; Mitchell et al.,
2001). Unlike other IκBs, BCL3 is a predominantly nuclear protein,
containing a transactivation domain, and can be recruited to NFκB-re-
sponsive promoters. This results in a transcriptional activation or re-
pression, depending on the composition of NFκB complexes (Ge et al.,
2003). Overexpression of BCL3 is also directed to an increased survival,
cell proliferation and malignant potential.
The hallmark of NFKBI protein family is the presence of multiple
ankyrin repeats and their ability to associate with the NF-κB protein.
The NFKBIA (IκBα) is characterized by 3 regions: an N-terminal region
with phosphorylation sites, a C-terminal PEST region regulating basal
degradation and an ankyrin repeat domain (Jacobs and Harrison, 1998;
Zhao et al., 2014). The NFKBIA gene is found on chromosome 14 and
contains 6 exons. Polymorphisms and haplotypes of NFKBIA and mu-
tations have been found in many diseases such as melanoma, Hodgkin's
lymphoma, colorectal cancer, hepatocellular carcinoma, multiple
myeloma or breast cancer (He et al., 2009; Liu et al., 2010; Bu et al.,
Table 1
Molar mass (MMa) for synthesized dendrimers, with the number and the per-
centage of surface maltotriose groups.
Dendrimer MM [g/mol] Number (percentage) of surface M3 groups
PPI-G4-OS-M3 14,260 22 (35%)
PPI-G4-DS-M3 31,000 56 (87%)
a MM of glycodendrimer determined by 1H NMR approach [(500MHz, D2O,
δ) for the molar ratio between x-times of 2 protons for anomeric H of mal-
totriose and 124 protons for internal CH2 groups, used as reference, of dendritic
poly(propylene imine) scaﬀold: 4.9–5.3 (s, x-time 2H, anomeric H of mal-
totriose) and 1.4–2.3 ppm (124H for internal CH2-groups).] approach described
in (Mkandawire et al., 2009).
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2007; Spink et al., 2007). Alterations render NFKBIA proteins important
from a clinical point of view mainly because they are incapable of in-
teracting with NF-κB, NFKBIA lose their activity, and thus resulting in
the loss of protection of tumor cells from apoptosis. RELB silencing may
be involved in the development of resistant subtypes of CLL in males
(Marteau et al., 2010). Our results show that glycodendrimers increase
the expression of this gene.
Lymphoid microenvironment promotes survival, proliferation and
ﬁnally progression of CLL cells through chronic activation of NF-κB
while suppressing the immune response (Mittal et al., 2014). In the
current study, we show that the addition of PPI-G4-OS-M3 and PPI-G4-
DS-M3 dendrimers to B-CLL cells signiﬁcantly induces apoptosis phe-
nomenon within this lymphocytes by signiﬁcant reduction of their
survival ratio.
Since 2012 our team has investigated the PPI-G4-M3 dendrimers as
potential drug in CLL therapy (Franiak-Pietryga et al., 2013) evidently
proving that PPI glycodendrimers strongly inﬂuence the survival of
cancer cells by inducing apoptosis and inhibiting their proliferation but
do not exert signiﬁcantly harmful eﬀect on normal lymphocytes
(Franiak-Pietryga et al., 2013; Ziemba et al., 2014). Moreover, PPI-G4
glycodendrimers mainly modulate pro- and antiapoptotic gene and
protein expression in CLL cells (Franiak-Pietryga et al., 2017b).
5. Conclusions
According to our previous results, we can indicate many genetic
Fig. 2. A comparison between glycodendrimers (GD) and ﬂudarabine (FA) mode of action on NF-κB cell signaling pathway in chronic lymphocytic leukemia cells.
Table 2
NF-κB gene expression in MEC-1 cells under the inﬂuence of PPI-G4-OS-M3, PPI-G4-DS-M3 and FA in 4-h-cultures; comparison with Ref.
Probe set Gene symbol Gene full name LogFC Statistical analysis P value
PPI-G4-OS-M3/
Ref
P330895 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, beta 1.2943 0.0002
P56938 REL V-rel avian reticuloendotheliosis viral oncogene homolog 0.7639 0.0005
P106002 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alfa (IκBα) −0.6581 0.001
P55706 RELB V-rel avian reticuloendotheliosis viral oncogene homolog B 0.6076 0.002
P30655 NFKBIE Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, epsilon −0.8388 0.01
P3209433 RELA V-rel avian reticuloendotheliosis viral oncogene homolog A 0.2533 0.05
PPI-G4-DS-M3/Ref P56938 REL V-rel avian reticuloendotheliosis viral oncogene homolog 0.9975 0.0001
P330895 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, beta 1.2535 0.0002
P55706 RELB V-rel avian reticuloendotheliosis viral oncogene homolog B 0.6551 0.001
FA/Ref P56938 REL V-rel avian reticuloendotheliosis viral oncogene homolog 0.6598 0.001
P55706 RELB V-rel avian reticuloendotheliosis viral oncogene homolog B 0.6953 0.001
P330895 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta 0.8904 0.001
Table 3
Apoptotic gene expression in MEC-1 cells under the inﬂuence of glycodendrimers in 4-h-cultures; comparison with FA.
Probe set Gene symbol Gene full name LogFC Statistical analysis
P value
PPI-G4-OS-M3/FA P106002 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alfa (IκBα) −0.4580 0.04
P4662 BCL3 B-cell CLL/lymphoma 3 −0.6212 0.04
P3258141 CHUK Conserved helix-loop-helix ubiquitous kinase −0.3954 0.05
PPI-G4-DS-M3/FA P4662 BCL3 B-cell CLL/lymphoma 3 −0.6488 0.04
P56938 REL V-rel avian reticuloendotheliosis viral oncogene homolog 0.3376 0.06
P3258141 CHUK Conserved helix-loop-helix ubiquitous kinase (IKK1) −0.3363 0.08
P106002 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alfa 0.3208 0.09
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targets in CLL that glycodendrimers (GD) may work with. This is totally
diﬀerent from the drug currently available in the market. The eﬀect of
GD is based on triggering diﬀerent genes simultaneously, starting a
domino eﬀect with the rest of the pathways. The eﬀect of apoptosis
begins in the inner part of the cell as soon as the dendrimer is en-
docytozed. The apoptosis comes directly from the mitochondria and
secondly triggers external pathway. Since the mechanism starts in the
middle of cell, it is much easier to turn on diﬀerent genes simulta-
neously. This is the ‘trojan horse’ eﬀect – the most eﬃcient sort of
treatment. We already know a lot about GD but there are still uncharted
waters remaining where we can ﬁnd tremendous potential of GD in
biomedical applications. Thus, further research is fully justiﬁed for
validating the potential of glycodendrimers as polymeric drug under in
vivo conditions.
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